The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-nociceptive effects of dual neuropeptide antagonist therapy in mouse model of neuropathic and inflammatory pain

  • Kim, Min Su (Department of Rehabilitation Medicine, Wonkwang University College of Medicine) ;
  • Kim, Bo Yeon (Department of Rehabilitation Medicine, Wonkwang University College of Medicine) ;
  • Saghetlians, Allen (Salk Institute for Biological Studies) ;
  • Zhang, Xiang (Salk Institute for Biological Studies) ;
  • Okida, Takuya (Salk Institute for Biological Studies) ;
  • Kim, So Yeon (Department of Rehabilitation Medicine, Wonkwang University College of Medicine)
  • Received : 2021.12.20
  • Accepted : 2022.03.10
  • Published : 2022.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Neurokinin-1 (NK1) and calcitonin gene-related peptide (CGRP) play a vital role in pain pathogenesis, and these proteins' antagonists have attracted attention as promising pharmaceutical candidates. The authors investigated the anti-nociceptive effect of co-administration of the CGRP antagonist and an NK1 antagonist on pain models compared to conventional single regimens. Methods: C57Bl/6J mice underwent sciatic nerve ligation for the neuropathic pain model and were injected with 4% formalin into the hind paw for the inflammatory pain model. Each model was divided into four groups: vehicle, NK1 antagonist, CGRP antagonist, and combination treatment groups. The NK1 antagonist aprepitant (BIBN4096, 1 mg/kg) or the CGRP antagonist olcegepant (MK-0869, 10 mg/kg) was injected intraperitoneally. Mechanical allodynia, thermal hypersensitivity, and anxiety-related behaviors were assessed using the von Frey, hot plate, and elevated plus-maze tests. The flinching and licking responses were also evaluated after formalin injection. Results: Co-administration of aprepitant and olcegepant more significantly alleviated pain behaviors than administration of single agents or vehicle, increasing the mechanical threshold and improving the response latency. Anxiety-related behaviors were also markedly improved after dual treatment compared with either naive mice or the neuropathic pain model in the dual treatment group. Flinching frequency and licking response after formalin injection decreased significantly in the dual treatment group. Isobolographic analysis showed a meaningful additive effect between the two compounds. Conclusions: A combination pharmacological therapy comprised of multiple neuropeptide antagonists could be a more effective therapeutic strategy for alleviating neuropathic or inflammatory pain.

Keywords

Acknowledgement

This study was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (No. HI19C0750).

References

  1. Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain 2017; 18: 34. https://doi.org/10.1186/s10194-017-0741-2
  2. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014; 155: 654-62. https://doi.org/10.1016/j.pain.2013.11.013
  3. Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol 2019; 33: 2058738419838383. https://doi.org/10.1177/2058738419838383
  4. Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012; 153: 342-9. https://doi.org/10.1016/j.pain.2011.10.026
  5. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 2017; 158: 543-59. https://doi.org/10.1097/j.pain.0000000000000831
  6. Hunyady A, Hajna Z, Gubanyi T, Scheich B, Kemeny A, Gaszner B, et al. Hemokinin-1 is an important mediator of pain in mouse models of neuropathic and inflammatory mechanisms. Brain Res Bull 2019; 147: 165-73. https://doi.org/10.1016/j.brainresbull.2019.01.015
  7. Navratilova E, Porreca F. Substance P and inflammatory pain: getting it wrong and right simultaneously. Neuron 2019; 101: 353-5. https://doi.org/10.1016/j.neuron.2019.01.034
  8. Chen W, Marvizon JC. Neurokinin 1 receptor activation in the rat spinal cord maintains latent sensitization, a model of inflammatory and neuropathic chronic pain. Neuropharmacology 2020; 177: 108253. https://doi.org/10.1016/j.neuropharm.2020.108253
  9. Ramirez-Garcia PD, Retamal JS, Shenoy P, Imlach W, Sykes M, Truong N, et al. A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain. Nat Nanotechnol 2019; 14: 1150-9. https://doi.org/10.1038/s41565-019-0568-x
  10. Teodoro FC, Tronco Junior MF, Zampronio AR, Martini AC, Rae GA, Chichorro JG. Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models. Neuropeptides 2013; 47: 199-206. https://doi.org/10.1016/j.npep.2012.10.005
  11. Gautam M, Prasoon P, Kumar R, Reeta KH, Kaler S, Ray SB. Role of neurokinin type 1 receptor in nociception at the periphery and the spinal level in the rat. Spinal Cord 2016; 54: 172-82. https://doi.org/10.1038/sc.2015.206
  12. Hirsch S, Corradini L, Just S, Arndt K, Doods H. The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats. Pain 2013; 154: 700-7. https://doi.org/10.1016/j.pain.2013.01.002
  13. Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G. Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Cephalalgia 2019; 39: 1827-37. https://doi.org/10.1177/0333102419861726
  14. Lee SE, Kim JH. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat. Neurosci Res 2007; 58: 245-9. https://doi.org/10.1016/j.neures.2007.03.004
  15. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9: 807-19. https://doi.org/10.1016/S1474-4422(10)70143-5
  16. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev 2021; 101: 259-301. https://doi.org/10.1152/physrev.00045.2019
  17. Hama A, Sagen J. Selective antinociceptive effects of a combination of the N-methyl-D-aspartate receptor peptide antagonist [Ser(1)]histogranin and morphine in rat models of pain. Pharmacol Res Perspect 2014; 2: e00032. https://doi.org/10.1002/prp2.32
  18. Michot B, Bourgoin S, Viguier F, Hamon M, Kayser V. Differential effects of calcitonin gene-related peptide receptor blockade by olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain 2012; 153: 1939-48. https://doi.org/10.1016/j.pain.2012.06.009
  19. Betti C, Starnowska J, Mika J, Dyniewicz J, Frankiewicz L, Novoa A, et al. dual alleviation of acute and neuropathic pain by fused opioid agonist-neurokinin 1 antagonist peptidomimetics. ACS Med Chem Lett 2015; 6: 1209-14. https://doi.org/10.1021/acsmedchemlett.5b00359
  20. Kang SJ, Liu S, Ye M, Kim DI, Kim JH, Oh TG, et al. Unified neural pathways that gate affective pain and multisensory innate threat signals to the amygdala. BioRxiv. 2020.11.17.385104 [Preprint]. 2020 [cited 2020 Nov 18]. Available from: https://doi.org/10.1101/2020.11.17.385104.
  21. Medeiros P, Dos Santos IR, Junior IM, Palazzo E, da Silva JA, Machado HR, et al. An adapted chronic constriction injury of the sciatic nerve produces sensory, affective, and cognitive impairments: a peripheral mononeuropathy model for the study of comorbid neuropsychiatric disorders associated with neuropathic pain in rats. Pain Med 2021; 22: 338-51. https://doi.org/10.1093/pm/pnaa206
  22. Mannangatti P, Sundaramurthy S, Ramamoorthy S, Jayanthi LD. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. Psychopharmacology (Berl) 2017; 234: 695-705. https://doi.org/10.1007/s00213-016-4504-6
  23. Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K, et al. Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 2020; 88: 771-84. https://doi.org/10.1002/ana.25831
  24. Lee IO, Jeong YS. Effects of different concentrations of formalin on paw edema and pain behaviors in rats. J Korean Med Sci 2002; 17: 81-5. https://doi.org/10.3346/jkms.2002.17.1.81
  25. Greco R, Mangione AS, Siani F, Blandini F, Vairetti M, Nappi G, et al. Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia 2014; 34: 594-604.
  26. Zhuo M. Neural mechanisms underlying anxiety-chronic pain interactions. Trends Neurosci 2016; 39: 136-45. https://doi.org/10.1016/j.tins.2016.01.006
  27. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007; 2: 322-8. https://doi.org/10.1038/nprot.2007.44
  28. Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Protoc Pharmacol 2016; 72: 9.19.1-19. https://doi.org/10.1002/0471141755.ph0919s72
  29. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006; 59: 216-23. https://doi.org/10.1016/j.biopsych.2005.07.013
  30. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, et al. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One 2011; 6: e24180. https://doi.org/10.1371/journal.pone.0024180
  31. Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 2016; 36: 887-98. https://doi.org/10.1177/0333102416653233
  32. Herbert MK, Holzer P. [Why are substance P(NK1)-receptor antagonists ineffective in pain treatment?]. Anaesthesist 2002; 51: 308-19. German. https://doi.org/10.1007/s00101-002-0296-7
  33. Hill R. NK1 (substance P) receptor antagonists--why are they not analgesic in humans? Trends Pharmacol Sci 2000; 21: 244-6. https://doi.org/10.1016/S0165-6147(00)01502-9
  34. Kroenke K, Outcalt S, Krebs E, Bair MJ, Wu J, Chumbler N, et al. Association between anxiety, health-related quality of life and functional impairment in primary care patients with chronic pain. Gen Hosp Psychiatry 2013; 35: 359-65. https://doi.org/10.1016/j.genhosppsych.2013.03.020
  35. De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 2019; 160: 136-50. https://doi.org/10.1097/j.pain.0000000000001386
  36. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004; 111: 77-83. https://doi.org/10.1016/j.pain.2004.06.002
  37. Roeska K, Doods H, Arndt K, Treede RD, Ceci A. Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. Pain 2008; 139: 349-57. https://doi.org/10.1016/j.pain.2008.05.003
  38. Wu Y, Yao X, Jiang Y, He X, Shao X, Du J, et al. Pain aversion and anxiety-like behavior occur at different times during the course of chronic inflammatory pain in rats. J Pain Res 2017; 10: 2585-93. https://doi.org/10.2147/jpr.s139679
  39. Munoz M, Covenas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids 2014; 46: 1727-50. https://doi.org/10.1007/s00726-014-1736-9
  40. Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, Bettelini L, al. Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 2003; 345: 73-6. https://doi.org/10.1016/S0304-3940(03)00305-7
  41. Borbely E, Hajna Z, Nabi L, Scheich B, Tekus V, Laszlo K, et al. Hemokinin-1 mediates anxiolytic and anti-depressant-like actions in mice. Brain Behav Immun 2017; 59: 219-32. https://doi.org/10.1016/j.bbi.2016.09.004
  42. Schorscher-Petcu A, Austin JS, Mogil JS, Quirion R. Role of central calcitonin gene-related peptide (CGRP) in locomotor and anxiety- and depression-like behaviors in two mouse strains exhibiting a CGRP-dependent difference in thermal pain sensitivity. J Mol Neurosci 2009; 39: 125-36. https://doi.org/10.1007/s12031-009-9201-z
  43. Araya EI, Turnes JM, Barroso AR, Chichorro JG. Contribution of intraganglionic CGRP to migraine-like responses in male and female rats. Cephalalgia 2020; 40: 689-700. https://doi.org/10.1177/0333102419896539
  44. Puig S, Sorkin LS. Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain 1996; 64: 345-55. https://doi.org/10.1016/0304-3959(95)00121-2
  45. Cho SY, Park AR, Yoon MH, Lee HG, Kim WM, Choi JI. Antinociceptive effect of intrathecal nefopam and interaction with morphine in formalin-induced pain of rats. Korean J Pain 2013; 26: 14-20. https://doi.org/10.3344/kjp.2013.26.1.14
  46. Rivat C, Laboureyras E, Laulin JP, Le Roy C, Richebe P, Simonnet G. Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats. Neuropsychopharmacology 2007; 32: 2217-28. https://doi.org/10.1038/sj.npp.1301340